Screener
TG Therapeutics TGTX EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from TG Therapeutics’s reported figures.
Based on trailing twelve months.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
FAQ
- What is TG Therapeutics's EBITDA margin?
- TG Therapeutics (TGTX) reported EBITDA margin of 17.1% in Q2 2026.
- How has TG Therapeutics's EBITDA margin changed year-over-year?
- TG Therapeutics's EBITDA margin decreased by 9.8% year-over-year, from 18.9% to 17.1%.
- What is the long-term trend for TG Therapeutics's EBITDA margin?
- Over 4 years (2020 to 2025), TG Therapeutics's EBITDA margin has grown at a -89.7% compound annual growth rate (CAGR), from -179,857.2% to 20%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about TG Therapeutics's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude